HCC

Arctic Wolf Threat Report Highlights Sharp Rise in Ransom Demands and BEC Incidents

Retrieved on: 
Mardi, février 20, 2024

EDEN PRAIRIE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arctic Wolf ®, a global leader in security operations, today published its annual Arctic Wolf Labs Threat Report .

Key Points: 
  • EDEN PRAIRIE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arctic Wolf ®, a global leader in security operations, today published its annual Arctic Wolf Labs Threat Report .
  • Created with threat, malware, digital forensics, and incident response case data that Arctic Wolf collects across the entire security operations framework, the Arctic Wolf Labs Threat Report delves deep into the cybercrime ecosystem, highlighting current global threat trends and offering strategic cybersecurity recommendations for the year ahead.
  • “Resources like the Arctic Wolf Labs Threat Report assist carriers and businesses in understanding the current and future cybersecurity landscape.
  • For additional insights from the 2024 Arctic Wolf Labs Threat Report, visit arcticwolf.com to download the full report .

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

Retrieved on: 
Jeudi, février 29, 2024

Key findings include that TriNav patients, despite a higher baseline disease burden and clinical complexity, showed overall clinical results comparable to patients with lower disease burden.

Key Points: 
  • Key findings include that TriNav patients, despite a higher baseline disease burden and clinical complexity, showed overall clinical results comparable to patients with lower disease burden.
  • In a matched cohort comparison, TriNav patients had fewer 30-day inpatient visits post-procedure than non-TriNav patients.
  • TriNav TARE patients with liver metastases had fewer clinical complications post-procedure vs. non-TriNav patients in a matched cohort comparison.
  • “This large sample size study underscores the particular benefits of the TriNav device compared to standard drug delivery systems.”

KAID Health launches PRIDE™ HCC coding technology and supporting services

Retrieved on: 
Jeudi, février 29, 2024

This new technology and the medical coding services organization help providers code more accurately and completely while improving care.

Key Points: 
  • This new technology and the medical coding services organization help providers code more accurately and completely while improving care.
  • KAID Health has already proven its technology can reduce labor costs and audit risks, including allowing healthcare organizations to appropriately navigate the challenges of HCC v28 and other risk-adjustment models.
  • In addition to launching PRIDE, KAID Health has created a technology-powered Coding Services Group.
  • KAID Health’s Coding Services Group delivers providers best-in-class coder training, physician education, and outsourcing options, making HCC improvement effortless.

Median Technologies to Participate and Speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria

Retrieved on: 
Lundi, février 26, 2024

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.
  • Philippe Grenier, Thoracic Radiologist and Head of the Artificial Intelligence project, Foch Hospital, Saint Cloud, France and Pr.
  • The European Congress of Radiology (ECR) organized by the European Society of Radiology (ESR) is the premier European event in radiology and the second largest in the world.
  • The congress conveys more than 20,000 with a split of more than 10,000 professional delegates (radiologists, technologists etc.

Warrior Met Coal CEO and CFO to Attend 2024 BMO Global Metals, Mining & Critical Minerals Conference

Retrieved on: 
Mercredi, février 21, 2024

Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) announced today that its Chief Executive Officer Walt Scheller and Chief Financial Officer Dale Boyles will attend the 2024 BMO Global Metals, Mining & Critical Minerals Conference February 26, 2024 – February 28, 2024.

Key Points: 
  • Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) announced today that its Chief Executive Officer Walt Scheller and Chief Financial Officer Dale Boyles will attend the 2024 BMO Global Metals, Mining & Critical Minerals Conference February 26, 2024 – February 28, 2024.
  • Warrior is a U.S.-based, environmentally, and socially minded supplier to the global steel industry.
  • It is dedicated entirely to mining non-thermal met coal used as a critical component of steel production by metal manufacturers in Europe, South America and Asia.
  • Warrior is a large-scale, low-cost producer and exporter of premium quality met coal, also known as hard-coking coal (“HCC”), operating highly efficient longwall operations in its underground mines based in Alabama.

Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer

Retrieved on: 
Mardi, février 20, 2024

Atezolizumab and bevacizumab is the first cancer immunotherapy combination regimen approved by the U.S. Food and Drug Administration for this setting and is the recommended standard of care by the National Comprehensive Cancer Network.

Key Points: 
  • Atezolizumab and bevacizumab is the first cancer immunotherapy combination regimen approved by the U.S. Food and Drug Administration for this setting and is the recommended standard of care by the National Comprehensive Cancer Network.
  • “We are excited to work with Roche to accelerate the development of IO-108,” said Charlene Liao, Ph.D., chief executive officer and board chair of Immune-Onc.
  • “IO-108 has demonstrated clinical activity and an acceptable safety profile across multiple solid tumors as monotherapy and in combination with T cell checkpoint inhibitors.
  • The collaboration marks a significant milestone in establishing IO-108 as the preferred myeloid checkpoint inhibitor for combination with standard of care immunotherapy regimens in solid tumors.”
    Under the collaboration, Roche will sponsor and conduct the global, randomized Phase 1b/2 trial to evaluate the safety, efficacy and pharmacodynamics of IO-108 in combination with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab, the standard of care treatment regimen for advanced liver cancer.

TAG - The Aspen Group, Women Employed, and Midwestern Career College Announce Partnership to Help Low-Income Chicago Women Establish Careers in Dentistry

Retrieved on: 
Jeudi, mars 7, 2024

"The first step in achieving equitable and inclusive care is having a diverse workforce that can serve the specialized needs of our patients.

Key Points: 
  • "The first step in achieving equitable and inclusive care is having a diverse workforce that can serve the specialized needs of our patients.
  • Our goal is to provide integrity, excellence, academic training, and a career-oriented approach in the field of dentistry to help women advance and achieve their career goals.
  • These unique experiences enable new graduates to launch successful careers in the field of dentistry while including the talent of women in the workplace."
  • The program is now enrolling its next class and women interested can go to mccollege.edu/dental-assisting to apply today.

Reveleer Secures $65 Million in Financing to Drive Strategic Expansion and Enhance Product Offerings

Retrieved on: 
Lundi, février 26, 2024

We are excited to have Hercules Capital, Inc. as a new financial partner."

Key Points: 
  • We are excited to have Hercules Capital, Inc. as a new financial partner."
  • "We are enthusiastic about the opportunities automation has unlocked for value-based care models nationwide," said Andrew Adams, Co-Founder and Managing Partner at Oak HC/FT.
  • These strategic acquisitions underscore Reveleer's commitment to advancing value-based care objectives by proactively addressing care gaps, enhancing patient outcomes, and optimizing financial performance.
  • Backed by recent capital investments, Reveleer continues its momentum to expand its offerings for payers and providers, delivering the market's most comprehensive workflow, data, and analytics solutions.

GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.

Retrieved on: 
Lundi, février 26, 2024

(Link)

Key Points: 
  • (Link)
    Through this agreement with BioCentriq, GC Cell is accelerating the transfer of Immuncell-LC Inj.
  • YONGIN, South Korea and NEWARK, N.J., Feb. 26, 2024 /PRNewswire/ -- GC Cell , a fully integrated cell therapy pioneer has announced a strategic partnership with BioCentriq , a cell therapy contract development and manufacturing organization (CDMO) and US affiliate of GC Cell.
  • "The Process Transfer Agreement between GC Cell and BioCentriq initiates the groundwork for introducing Immuncell-LC to the U.S. market" said James Park, CEO of GC Cell.
  • "We are thrilled to partner with GC Cell to bring Immuncell-LC, a proven autologous cell therapy to the U.S. Market.

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments

Retrieved on: 
Mardi, février 20, 2024

Unfortunately, key members of this pathway (including beta-catenin) have either been resistant to conventional drug development or plagued with off-target toxicities.

Key Points: 
  • Unfortunately, key members of this pathway (including beta-catenin) have either been resistant to conventional drug development or plagued with off-target toxicities.
  • Extensive pre-clinical study results across multiple tumor types suggest that TBL1 is a downstream target that is necessary for Wnt/beta-catenin-activated oncogenesis.
  • Tegavivint has demonstrated safety, clinical and pharmacodynamic activity in a Phase 1 clinical study of patients with desmoid tumors.
  • For more information about this Phase 1b/2a clinical trial of tegavivint in patients with advanced HCC, please visit www.ClinicalTrials.gov using the identifier NCT05797805.